January 2025
Sanofi Assures No Supply Disruptions Following FDA Warning Letter for US Manufacturing Site
Sanofi, FDA warning letter, US manufacturing site, supply interruptions, CGMP deviations
Trump’s Second Term: Mifepristone Battle Looms as Early Test of Abortion Stance
Mifepristone, abortion, Trump, second term, reproductive rights, FDA, Supreme Court
Biotech IPO Market Expected to Rebound in 2025 with Increased Investor Optimism
Biotech IPOs, 2025 Outlook, Investor Optimism, Therapeutic Innovation, Strategic Differentiation
Trump Withdraws US from World Health Organization, Sparking Concerns Over Global Health Security
Trump, World Health Organization, WHO, withdrawal, global health security, infectious diseases, pandemics, COVID-19, public health experts.
InnoCare and KeyMed Secure $520M Licensing Deal for Bispecific Antibody with RTW-Built Biotech
InnoCare, KeyMed, Bispecific Antibody, RTW Investments, Licensing Deal, $520M
Atara Biotherapeutics Faces Clinical Hold on EBVALLO and Pipeline Candidate Due to Manufacturing Site Inspection Issues
Atara Biotherapeutics, EBVALLO, Clinical Hold, FDA, Manufacturing Site Inspection, Cell Therapy, T-Cell Immunotherapy
Empowering Women’s Health: First Lady Jill Biden and Biopharma Leaders Unite at JPM25
JPM25, Women’s Health, First Lady Jill Biden, Biopharma, Healthcare Investment, J.P. Morgan Healthcare Conference
FDA Urges Enhanced Authority to Combat Pediatric and Neonatal Medical Device Shortages
FDA, Medical Device Shortages, Pediatric Patients, Neonatal Patients, Supply Chain Vulnerabilities, Regulatory Authority
Boehringer Ingelheim’s Iclepertin Fails to Meet Primary and Secondary Endpoints in Phase III Schizophrenia Trials
Boehringer Ingelheim, iclepertin, schizophrenia, Phase III trials, cognitive impairment, CONNEX program
High-Dose Wegovy Demonstrates Enhanced Weight Loss in Phase III Trial
Wegovy, semaglutide, obesity treatment, weight loss, Novo Nordisk, Phase III trial, STEP UP trial